Elizabeth Brettell is the Renal Trials Portfolio Manager at the Birmingham Clinical Trials Unit (BCTU).
Elizabeth has worked at BCTU since 1998 co-ordinating large randomised controlled clinical trials in Alzheimer’s Disease, Acute Myeloid Leukaemia, women’s health and renal disease.
Elizabeth qualified with a BSc Hons (Tech.) in Applied Biology from Cardiff University in 1994. After travelling in Asia and working at the Orthotic Department of Torbay Hospital, Elizabeth joined the Academic Department of Geriatric Medicine at Selly Oak Hospital as a Research Assistant working on a study assessing the impact of a lifestyle intervention for patients aged over 65 who had been admitted to hospital with myocardial infarction or unstable angina.
Elizabeth then joined the BCTU in 1998 where she co-ordinated the UK multi-centre AD2000 study which assessed the safety and efficacy of donepezil and aspirin in Alzheimer’s disease, the results of which were published in the name of the AD2000 collaborative group in the Lancet in 2004 generating worldwide interest. Elizabeth was credited for her role of overall trial management of AD2000 by listing in the writing committee and contributors group.
Elizabeth then managed, administered and co-ordinated the MRC/NCRI Acute Myeloid Leukaemia (AML) trials portfolio. The portfolio included three large international trials, and the annual follow-up of all patients recruited to AML trials over the past thirty years. Elizabeth’s co-ordination of both AD2000 and the AML trials has brought together reliable clinical trial evidence to guide future prescribing practice within the NHS.
Before leaving for a sabbatical Elizabeth successfully set-up the OPT trial. OPT is a non-inferiority trial that aims to determine reliably whether out-patient polyp removal under local anaesthetic is clinically as effective as in-patient surgery for women with uterine polyps, and to determine the relative cost-effectiveness of each strategy.
After Elizabeth returned from a sabbatical in 2010, she managed the set up of the new BCTU renal trials portfolio. The portfolio includes the ASTRAL trial which is in follow-up and the new trials GloMY, PEXIVAS and PREDNOS.
Elizabeth was co-ordinator of the AD2000 trial which assessed the safety and efficacy of donepezil and aspirin in Alzheimer’s disease.
Acute Myeloid Leukaemia (AML)
Elizabeth administered and co-ordinated the MRC/NCRI AML trials portfolio. This portfolio included AML14, AML15 and AML16.
Abnormal Uterine Bleeding
Elizabeth set-up and co-ordinated the OPT trial which was a randomised controlled trial of Outpatient Polyp Treatment for Abnormal Uterine Bleeding.
Elizabeth manages the BCTU renal trials portfolio which includes the following trials:
ASTRAL - Angioplasty and STent for Renal Arterial Lesions
GloMY - A UK, multi centre, randomised controlled open label pilot trial of Myfortic plus short course steroids versus high-dose prolonged course steroid in patients with proteinuric FSGS and/or no additional IgA nephropathy.
PEXIVAS - An international randomised controlled trial of plasma exchange and glucocorticoid dosing in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis.
PREDNOS - Long-term tapering versus standard prednisolone (steroid) therapy for the treatment of the initial episode of childhood nephrotic syndrome: national multicentre randomised double blind trial.
AD2000 Collaborative Group (Writing Committee: Gray R, Bentham P, Hills R, Raftery J, Sellwood E, and Crome P). Aspirin in Alzheimer’s disease (AD2000): a randomised open label trial. Lancet Neurol 2008;7:41-49.
AD2000 Collaborative Group (Writing Committee: Gray R, Bentham P, Hills R, Lendon C, Raftery J, Sellwood E, Courtney C, Crome P, Edwards S, Farrell D, Hardyman W, Lynch L, Shaw H). Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. Lancet 2004;363:2105-2115.
Crome P, Hills R, Bentham P, Courtney C, Edwards S, Gray R, Hardyman W, Raftery J, Sellwood E, for the AD2000 Collaborative Group. Effect of aspirin on the progression of Alzheimer’s disease. Journal of the American Geriatrics Society 2004;52:S204 (Abstract P546).
Crome P, Hills R, Bentham P, Courtney C, Edwards S, Gray R, Hardyman W, Raftery J, Sellwood E, for the AD2000 Collaborative Group. Effect of aspirin on the progression of Alzheimer's disease (AD). Age and Ageing 2004;33 Suppl 2:ii38 (Abstract).
Crome P, Hills R, Bentham P. Courtney C, Edwards S, Gray R, Hardyman W, Raftery J, Sellwood E for AD2000 Collaborative Group. Effects of discontinuing donepezil treatment on cognition and function in patients with Alzheimer’s disease. Age and Ageing 2006;35;Suppl 1:i69.
Hills RK, Gray R, Bentham P, Sellwood E, for the AD2000 Study Group. N of 1 trials are an ineffective method of identifying treatment responders. Clinical Trials 2005;2;Suppl 1:S32 (Abstract 22).